Literature DB >> 34757582

Evaluation of Intra-Renal Stiffness in Patients with Primary Aldosteronism.

Luigi Petramala1, Antonio Concistrè1, Francesco Circosta1, Antonietta Gigante1, Francesca Sarlo2, Mauro Schina3, Maurizio Soldini1, Gino Iannucci3, Rosario Cianci1, Claudio Letizia4.   

Abstract

INTORDUCTION: Aldosterone is known to play important role in developing cardiovascular, metabolic, renal damage in hypertensive patients. AIM: Aim of study was to evaluate parameters obtained by eco-color Doppler study, as non-invasive and easly performed method in asyntomatic patients with Essential Hypertension (EH) and Primary Aldosteronism (PA), without overt organ damage.
METHODS: From April 2019 to March 2020 we consecutively enrolled 73 hypertensive subjects (48 males, 25 women), distinguished in two groups: 30 EH patients (mean age 49.5 ± 18.7 years) and 43 PA patients (mean age 53.1 ± 11.6 years)] [23 with aldosterone-secreting adrenal adenoma (APA), 20 with idiopathic aldosteronism (IHA)].
RESULTS: PA group showed higher renal filtration rate and 24-h urinary excretion of albumin respect to EH; moreover, in PA we found higher Pulsatility Index, altered percentage of Renale Resistance Index, Atrophy Index, and reducted parietal thickness than EH. The correlation study showed that plasma aldosterone were positively correlated with pulsatility index in PA group (right r = 0.35; p < 0.05; left r = 0.36; p < 0.05).
CONCLUSION: parameters obtained through the intra-renal eco-color Doppler examination, easly performed and non-invasive, can be useful in the early-stage identification of subclinical microvascular alterations, especially in PA, condition characterized by increased risk of cardio-vascular remodelling and metabolic alterations.
© 2021. Italian Society of Hypertension.

Entities:  

Keywords:  Cardio-vascular risk; Eco-color Doppler study; Intra-renal stiffness; Primary aldosteronism

Mesh:

Substances:

Year:  2021        PMID: 34757582     DOI: 10.1007/s40292-021-00485-3

Source DB:  PubMed          Journal:  High Blood Press Cardiovasc Prev        ISSN: 1120-9879


  18 in total

1.  Enhanced Soluble Serum CD40L and Serum P-Selectin Levels in Primary Aldosteronism.

Authors:  L Petramala; G Iacobellis; R Carnevale; C Marinelli; L Zinnamosca; A Concistrè; M Galassi; G Iannucci; P Lucia; P Pignatelli; A Ciardi; F Violi; G De Toma; C Letizia
Journal:  Horm Metab Res       Date:  2016-04-21       Impact factor: 2.936

2.  2018 ESC/ESH Guidelines for the management of arterial hypertension.

Authors:  Bryan Williams; Giuseppe Mancia; Wilko Spiering; Enrico Agabiti Rosei; Michel Azizi; Michel Burnier; Denis L Clement; Antonio Coca; Giovanni de Simone; Anna Dominiczak; Thomas Kahan; Felix Mahfoud; Josep Redon; Luis Ruilope; Alberto Zanchetti; Mary Kerins; Sverre E Kjeldsen; Reinhold Kreutz; Stephane Laurent; Gregory Y H Lip; Richard McManus; Krzysztof Narkiewicz; Frank Ruschitzka; Roland E Schmieder; Evgeny Shlyakhto; Costas Tsioufis; Victor Aboyans; Ileana Desormais
Journal:  Eur Heart J       Date:  2018-09-01       Impact factor: 29.983

3.  Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.

Authors:  Paul Milliez; Xavier Girerd; Pierre-François Plouin; Jacques Blacher; Michel E Safar; Jean-Jacques Mourad
Journal:  J Am Coll Cardiol       Date:  2005-04-19       Impact factor: 24.094

4.  Adipokines and cardiometabolic profile in primary hyperaldosteronism.

Authors:  Gianluca Iacobellis; Luigi Petramala; Dario Cotesta; Mario Pergolini; Laura Zinnamosca; Rosario Cianci; Giorgio De Toma; Susanna Sciomer; Claudio Letizia
Journal:  J Clin Endocrinol Metab       Date:  2010-03-01       Impact factor: 5.958

5.  A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients.

Authors:  Gian Paolo Rossi; Giampaolo Bernini; Chiara Caliumi; Giovambattista Desideri; Bruno Fabris; Claudio Ferri; Chiara Ganzaroli; Gilberta Giacchetti; Claudio Letizia; Mauro Maccario; Francesca Mallamaci; Massimo Mannelli; Mee-Jung Mattarello; Angelica Moretti; Gaetana Palumbo; Gabriele Parenti; Enzo Porteri; Andrea Semplicini; Damiano Rizzoni; Ermanno Rossi; Marco Boscaro; Achille Cesare Pessina; Franco Mantero
Journal:  J Am Coll Cardiol       Date:  2006-11-13       Impact factor: 24.094

6.  The Renal Resistive Index in systemic sclerosis: Determinants, prognostic implication and proposal for specific age-adjusted cut-offs.

Authors:  Cosimo Bruni; Edoardo Rosato; Vanessa Maestripieri; Antonietta Gigante; Giulia Tesei; Silvia Bellando-Randone; Serena Guiducci; Marco Chiostri; Khadija El Aoufy; Jelena Blagojevic; Alberto Moggi-Pignone; Amato De Paulis; Daniel E Furst; Maria Boddi; Marco Matucci-Cerinic
Journal:  Eur J Intern Med       Date:  2019-09-17       Impact factor: 4.487

Review 7.  The internist and the renal resistive index: truths and doubts.

Authors:  Maria Boddi; Fabrizia Natucci; Elisa Ciani
Journal:  Intern Emerg Med       Date:  2015-09-04       Impact factor: 3.397

8.  Atrial fibrillation as presenting sign of primary aldosteronism: results of the Prospective Appraisal on the Prevalence of Primary Aldosteronism in Hypertensive (PAPPHY) Study.

Authors:  Teresa M Seccia; Claudio Letizia; Maria L Muiesan; Silvia Lerco; Maurizio Cesari; Valeria Bisogni; Luigi Petramala; Giuseppe Maiolino; Roberta Volpin; Gian Paolo Rossi
Journal:  J Hypertens       Date:  2020-02       Impact factor: 4.844

9.  Oxidative stress in patients affected by primary aldosteronism.

Authors:  Luigi Petramala; Pasquale Pignatelli; Roberto Carnevale; Laura Zinnamosca; Cristiano Marinelli; Amina Settevendemmie; Antonio Concistrè; Gianfranco Tonnarini; Giorgio De Toma; Francesco Violi; Claudio Letizia
Journal:  J Hypertens       Date:  2014-10       Impact factor: 4.844

Review 10.  Gray Scale Ultrasound, Color Doppler Ultrasound, and Contrast-Enhanced Ultrasound in Renal Parenchymal Diseases.

Authors:  Emilio Quaia; Jean Michel Correas; Maithili Mehta; John T Murchison; Antonio Giulio Gennari; Edwin J R van Beek
Journal:  Ultrasound Q       Date:  2018-12       Impact factor: 1.657

View more
  1 in total

Review 1.  Cerebro-Cardiovascular Risk, Target Organ Damage, and Treatment Outcomes in Primary Aldosteronism.

Authors:  Xiao Lin; Muhammad Hasnain Ehsan Ullah; Xiong Wu; Feng Xu; Su-Kang Shan; Li-Min Lei; Ling-Qing Yuan; Jun Liu
Journal:  Front Cardiovasc Med       Date:  2022-02-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.